Veracyte’s approach to improving thyroid cancer diagnosis
EXCEPTIONAL TESTING FOR THYROID CANCER
Clearer diagnosis and treatment planning with Afirma® Genomic Sequencing Classifier (GSC)
Veracyte developed the Afirma Genomic Sequencing Classifier to help physicians personalize thyroid cancer diagnosis and treatment decisions for their patients with thyroid nodules. Based on RNA whole-transcriptome sequencing and advanced machine-learning technology, the test identifies patients who do not have cancer when traditional testing fails to provide conclusive results. These patients may potentially avoid unnecessary surgery. When thyroid cancer is suspected, the test uses the largest panel of expressed gene alterations available to help inform treatment decisions.
Learn about Afirma GSC for thyroid cancer
Polavarapu P, et al. Journal of Endo Soc. 2021.
Melilo RM, et al. JCEM. 2012.
Cibas ES, et al. Ann Intern Med. 2013.
Cibas ES, et al. Thyroid. 2017.
Company estimates based on Bethesda criteria of B-III/IV and B-V/VI in the US only.
The Afirma Genomic Sequencing Classifier is available in the US as part of Veracyte’s CLIA-validated laboratory developed test (LDT) service. This test has not been cleared or approved by the FDA.
This website contains information on products that are targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for you accessing such information that may not comply with any legal process, regulation, registration or usage in the country of your origin.